Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
This cohort study, conducted at a single center, highlights that LTBI can reduce gut microbiota diversity among adult patient with UC. The observed efficacy of vedolizumab treatment in the LTBI group indicates a potential association with microbiota changes. However, mono-isoniazid exhibited limited impact, underscoring the potential of vedolizumab as a promising candidate for prophylactic anti-tuberculosis treatment in the context of UC.
Authors
- Lujian Zhu (ORCID: https://orcid.org/0009-0002-4996-1446)
- Zhenping Wu
- Hao Fang (ORCID: https://orcid.org/0009-0007-1368-4105)
- Xiaoyun Yang
- Minli Hu
- Qunying Wang (ORCID: https://orcid.org/0000-0003-4405-402X)
- Jin Ding
- Yibing Hu
Institutions
- Guang Fu Hospital (CN)
- Jinhua Central Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Microbiology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1186/s12866-024-03705-7
- Citations
- 1
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Department of Health of Zhejiang Province